pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›fenebrutinib
drug · small molecule
save

fenebrutinib

Phase 3updated 6mo ago
by Genentech Inc🔗 ChEMBL
Phase 3
community read0 votes

Small molecule drug with a maximum clinical stage of Phase 3 (across all indications), with 8 investigational indications.

targets

Tyrosine-protein kinase BTK

all catalysts(0)

nothing on the calendar yet

Trials studying fenebrutinib

  • phase2A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)recruitingn=12
  • phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)active not recruitingn=746
  • phase3A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosisactive not recruitingn=985
  • phase3Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)active not recruitingn=751
  • phase2A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)active not recruitingn=109

News(7)

  • STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
    An MS treatment from Novartis cut by a third the rates of relapses compared to a standard treatment.
    stat · 24d ago
  • Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches
    Roche has dived into the data behind its filing for FDA approval of fenebrutinib in multiple sclerosis, unpacking the BTK inhibitor’s effect on chronic active lesions, disease control and brain vol…
    fiercebiotech · 27d ago
  • FDA starts review of Roche’s multiple sclerosis pill
    The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety questions still hang over Roche’s program.
    biopharma_dive · 1mo ago
  • ‘We’re so close to the tech companies’: Genentech CEO talks Fierce through vision for the future
    When recombinant DNA pioneer Herbert Boyer, Ph.D., first got a call from venture capitalist Robert Swanson about starting a company, the savvy scientist wasn’t sure a meeting would be worth his time.
    fiercebiotech · 1mo ago
  • Roche, Ionis RNA drug scores in kidney disease study
    The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
    biopharma_dive · 1mo ago
  • Novartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
    Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche's own BTK inhibitor fenebrutinib.
    biospace · 2mo ago
  • Merck adds to pharma’s AI push; Roche details MS drug results
    Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…
    biopharma_dive · 6mo ago
generic
fenebrutinib
MOA
Tyrosine-protein kinase BTK inhibitor
indication
Primary Progressive Multiple Sclerosis (PPMS)
phase
phase_3
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 4h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?